TrumpRx Continues to Drive Pricing Chatter, With Attention on Generics and GoodRx
And there are still TrumpRx stories to be told, including an effort by Pfizer to use the platform in a low-key biosimilar price war
Feb 9, 2026
Subscribe to Cost Curve Apex to read the rest.
Upgrade to Apex to get access to this post and other subscriber-only content.
Upgrade